Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 10/20 | 0.70 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15034558 | 0.95 | GRM5 (0.68) | GRM5KDM4ESMN1; SMN2ALDH1A1HPGD | |
| SCHEMBL15034534 | 0.92 | GRM5 (0.59) | GRM5KDM4ESMN1; SMN2ALDH1A1TSHR | |
| SCHEMBL15034542 | 0.91 | GRM5 (0.61) | GRM5KDM4EL3MBTL1 | |
| SCHEMBL15034513 | 0.91 | GRM5 (0.55) | GRM5KDM4ESMN1; SMN2ALDH1A1TSHR | |
| SCHEMBL15034519 | 0.90 | KDM4E (0.57) | GRM5KDM4ESMN1; SMN2ALDH1A1TSHR | |
| SCHEMBL15034541 | 0.89 | GRM5 (0.64) | GRM5 | |
| SCHEMBL15034544 | 0.87 | GRM5 (0.64) | GRM5SMN1; SMN2ALDH1A1HPGDHSD17B10 | |
| SCHEMBL15034561 | 0.86 | GRM5 (0.67) | GRM5KDM4E | |
| SCHEMBL15034527 | 0.86 | HSD17B10 (0.59) | GRM5KDM4ESMN1; SMN2ALDH1A1TSHR | |
| SCHEMBL15034559 | 0.85 | HPGD (0.52) | GRM5KDM4ESMN1; SMN2ALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8937176-B2 | Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-01-20 | — | — | US | disclosed |
| US-8937176-B2 | Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-01-20 | — | — | US | disclosed |
| US-20130158038-A1 | NOVEL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-06-20 | — | — | US | disclosed |
| US-20130158038-A1 | NOVEL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130158038-A1 | NOVEL COMPOUNDS | GRM5, GRIN1, GRM1 | GRM5 1/4885KDM4E 1915/4885SMN1; SMN2 2436/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.